NEFL and familial dilated cardiomyopathy: [32] Additionally, research into the use of biomarkers to monitor DCM progression is emerging, with raised CSF neurofilament light subunit (NF-L) and glial fibrillary acidic protein (GFAP) as well as lower amyloid β peptide being correlated with symptom duration [54].